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Abstract
Defectiveregulationofapoptosismayplayaroleinthedevelopmentofautoimmunediseases.FasandBcl-2proteinsareinvolved
inthecontrolofapoptosis.TheaimsofthisstudyweretodeterminetheexpressionofFasantigenandBcl-2proteinonperipheral
bloodTandBlymphocytesfrompatientswithjuvenile-onsetsystemiclupuserythematosus(JSLE),juvenilerheumatoidarthritis
(JRA)andjuveniledermatomyositis(JDM).Thirty-eightpatientswithJSLE, 19patientswithJRA,10patientswithJDMand25
healthy controls entered the study. Freshly isolated peripheral blood mononuclear cells (PBMC) were stained for lymphocyte
markers CD3, CD4, CD8, CD19 and for Fas and Bcl-2 molecules. Expressions were measured by three-color ﬂow cytometry.
Statistical analysis was performed using Kruskal–Wallis test. Percentages of freshly isolated T lymphocytes positively stained for
Fas protein from JSLE patients were signiﬁcantly increased compared to healthy controls, patients with JRA and patients with
JDM. Percentages of B lymphocytes positive for Fas from JSLE patients were higher than healthy controls and JRA patients. In
addition,FasexpressiononTcellsfrompatientswithJRAwasincreasedcomparedtoJDMpatients.Otherwise,Fasexpressionon
TandBcellsfromJRAandJDMpatientsweresimilartohealthycontrols.MFIofBcl-2positiveTlymphocytesfromJSLEpatients
were signiﬁcantly increased compared to healthy controls and JRA patients. MFI of Bcl-2 protein on B lymphocytes from JSLE
patients was similar to healthy controls and patients with JRA and JDM. Bcl-2 expression did not differ between JRA and JDM
patients and healthy controls. In conclusion, increased expression of Fas and Bcl-2 proteins observed in circulating T and B
lymphocytes from patientswithJSLE, but not from patientswith JRA and JDM, suggests thatabnormalities of apoptosis may be
related to the pathogenesis of JSLE and probably are not a result of chronic inﬂammation.
Keywords: Juvenile systemic lupus erythematosus, juvenile rheumatoid arthritis, juvenile dermatomyositis, Fas antigen, Bcl-2
protein, apoptosis
Introduction
Juvenile systemic lupus erythematosus (JSLE), juven-
ile rheumatoid arthritis (JRA) and juvenile dermato-
myositis (JDM) are autoimmune diseases with high
morbidity and mortality in childhood (Behrens et al.
1997; Andrade et al. 2000; Szodoray et al. 2003).
These autoimmune diseases present dysfunction of T
and B cells causing tissue inﬁltration of mononuclear
cells and macrophages, tissue damage and production
of autoantibodies (Behrens et al. 1997; Andrade et al.
2000; Szodoray et al. 2003). Their etiopathogenesis
are not yet understood and it is possible that
abnormalities of apoptosis at the stage of lymphocytes
differentiation may be related to the presence of
autoreactive T and B cells on peripheral blood
(Behrens et al. 1997; Andrade et al. 2000; Kamradt
and Mitchinson 2001; Szodoray et al. 2003).
Additionally, increased rates of apoptotic cells may
lead to the presence of great amounts of nuclear
antigens at the extracellular tissue. These autoantigens
can thus be presented to auto-reactive lymphocytes
and drive to an autoimmune disease (Casciola-Rosen
et al. 1994; Emlen et al. 1994; Wyllie 1997; Andrade
et al. 2000; Smolewska et al. 2003).
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surface receptor. Mutations of Fas gene in MRL/Ipr
mice lead to the development of a lymphoproliferative
syndrome including features resembling lupus (Rieax-
Laucat et al. 1995; Drappa et al. 1996). Increased Fas
expression has been reported on peripheral T and B
cells from patients with lupus, on synovial ﬂuid cells
from patients with rheumatoid arthritis and on muscle
ﬁbres from patients with dermatomyositis (Ohsako
et al. 1994; Amasaki et al. 1995; Behrens et al. 1997;
Sioud et al. 1998; Sugiura et al. 1999; Bijl et al. 2001).
Bcl-2 protein inhibits apoptosis (Ivanovska et al.
2004). There is now considerable evidence that Bcl-2
expression is enhanced in peripheral T cells from
patients with lupus (Strasser et al. 1991; Aringer et al.
1994; Rose et al. 1994; Mehrian et al. 1998; Falcini
et al. 1999). Szodoray et al. (2003) observed increased
expression of Bcl-2 on peripheral lymphocytes from
patients with rheumatoid arthritis. In addition,
increased expression of Bcl-2 was reported on muscle
ﬁbres from patients with dermatomyositis (Behrens
et al. 1997; Falcini et al. 2000). Furthermore, the
relation between inducers and inhibitors of apoptosis
may differ according to cell type, to autoimmune
disease and to age of disease onset.
In patients with juvenile systemic lupus erythema-
tosus, JRA and JDM few number of studies
concerning apoptosis and lymphocyte expression of
Fas and Bcl-2 proteins have been performed. The
aims of the present study were to examine the
expression of Fas and Bcl-2 proteins in freshly isolated
T and B lymphocytes from patients with JSLE, JRA
and JDM.
Patients and methods
Thirty-eight consecutive JSLE patients (32 females
and 6 males; ages 8.2–20.9 years, mean age 14.0
years; mean disease duration 3.2 years) fulﬁlling at
least four of the ACR revised criteria for lupus (Tan
et al. 1982; Hochberg 1997), 19 patients with JRA (11
females and 8 males; ages 4.3–18.4 years, mean age
10.8 years) meeting the ACR criteria (Brewer et al.
1977) and 10 patients with JDM (4 females and 6
males; ages 3.4–13.2 years, mean age 9.3 years)
meeting the criteria established by Bohan and Peter
(1975) entered the study. Patients were recruited
from the Rheumatology Unit, Children’s Institute,
School of Medicine, University of Sa ˜o Paulo, from
April 2004 through March 2005. At disease onset all
patients were younger than 16 years. Twenty-ﬁve sex-
and age-matched healthy controls were also included
in the study. Informed consent was obtained from
all parents and the study was approved by the local
ethics committee.
JSLE patients were basically treated with oral
prednisone (0.5–1mg/Kg/day) and 16 patients
with severe disease were using immunosuppressive
medication. Three JRA patients were without treat-
ment, 15 were receiving nonsteroidal anti-inﬂamma-
tory drugs and 10 were using oral prednisone
associated with methotrexate or cyclosporine. Four
JDM patients were without treatment, 5 were using
oral prednisone associated with methotrexate or
cyclosporine and one was using only methotrexate.
Immunoﬂuorescence staining
Immediately after venous blood was collected in
EDTA tubes, peripheral blood mononuclear cells
(PBMC) were separated by total blood lysis (Marti
et al. 2001). Expression of Fas antigen and Bcl-2
protein on T and B lymphocytes was evaluated by
three- and two-color immunoﬂuorescence analysis.
Surface and cytoplasmatic staining were performed
with the following monoclonal antibodies: Fluorescein
isothiocyanate (FITC) conjugated monoclonal anti-
bodies against Fas (Becton-Dickinson-Pharmigen
(BD) mouse IgG1—555673), FITC-labeled anti-
Bcl-2 (BD hamster IgG2a—554234), phycoerythrine
(PE) conjugated monoclonal antibodies against CD4
(BD mouse IgG1—555347), PE-labeled anti-CD8
(BD mouse IgG1—555635), PE-labeled anti-CD19
(BD mouse IgG1—555413) and anti-CD3-Cy5 (BD
mouse IgG1—555334).
After one wash with phosphate buffered saline
(PBS) supplemented with 0.1% sodium azide,
1 £ 10
6/ml cells were resuspended in 50ml of PBS
containing 2% fetal bovine serum (FBS) and stained
with CD4, CD8, CD19, CD3 and Fas monoclonal
antibodies. After 20-minute incubation in the dark,
cells were lysed with 15-minute incubation in 10%
FACS lysing solution and washed two times with PBS
and resuspended using 1% paraformaldehyde prior to
ﬂow cytometric analysis.
For Bcl-2 protein intracytoplasmatic staining, cell
membranes were permebilized by incubation with 4%
paraformaldehyde and 10% FACS lysing solution for
10min, washed twice with 0.5% PBS-Tween and
FITC-labeled Bcl-2 was added. The CD4, CD8,
CD19 and CD3 staining and other procedures were
similar to Fas staining. Isotype controls were included
in all experiments.
Flow cytometric analysis
Immediately after staining procedure, ﬂow cytometry
analysis was done on a BD FAScan. Accurate physical
and immunological gating was performed using
CD3-Cy5. Positive and negative controls were run
for each sample in order to standardize FACS
procedures. During the 11-month duration of
this study there was no realignment of the cytometer.
Instrument settings were kept constant and
ﬂuorescence alignment constancy for forward scatter,
green ﬂuorescence and red ﬂuorescence were
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scatter proﬁles were identical for all patients and
controls analysed in parallel in each session. Ten
thousand lymphocytes were analysed per sample and
double positive cells identiﬁed by dot-plot histograms.
The results were expressed as percentage of double
staining cells in relation to the cellular total and as
mean ﬂuorescence intensity (MFI).
Statistical analysis
Data were analysed using SPSS for windows. To
determine if there were signiﬁcant differences between
lymphocyte Fas and Bcl-2 expressions from patients
and healthy controls the nonparametric Kruskal–
Wallis test was used (Rosner 2000). P values less than
0.05 were considered statistically signiﬁcant.
Results
Expression of Fas antigen
Percentages of freshly isolated lymphocytes positively
stained for Fas antigen from JSLE patients were
signiﬁcantly increased compared to healthy controls
on CD3 þ , on CD8 þ T cells and on CD19 þ B
cells. Fas expression on lymphocytes from JSLE
patients were also increased compared to JRA patients
on CD3 þ , CD8 þ T cells and on CD19 þ B and
compared to JDM patients on CD3 þ , CD4 þ and
CD8 þ T cells (Table I). JRA patients presented
percentages of lymphocytes positively stained for Fas
antigen signiﬁcantly increased compared to JDM
patients on CD3 þ (34.9 ^ 10.6 vs. 24.9 ^ 13.4;
p ¼ 0.02), on CD4 þ (18.2 ^ 3.9 vs. 13.0 ^ 4.0;
p ¼ 0.005) and on CD8 þ T cells (17.3 ^ 9.7 vs.
12.7 ^ 13.5; p ¼ 0.03). Otherwise, percentages of
positive cells and MFI of Fas antigen from patients
with JRA and JDM were similar to healthy controls
(Table I).
Expression of Bcl-2 protein
The density of Bcl-2 protein (MFI) on lymphocytes
from JSLE patients were signiﬁcantly increased
(p , 0.05) compared to healthy controls on
CD3 þ ,o nC D 4þ and on CD8 þ T cells, but not
on CD19 þ B cells. MFI of Bcl-2 was also increased
on lymphocytes from JSLE patients compared to JRA
patients on CD3 þ , CD4 þ and CD8 þ T cells, but
there was no difference compared to JDM patients
(Table II). Bcl-2 protein expression on T and B
lymphocytes from patients with JRA and JDM did not
differ from healthy controls. And there was no
difference between Bcl-2 expression on Tand B cells
from JRA and JDM patients (Table II).
Discussion
The present study showed increased expression of Fas
and Bcl-2 proteins on peripheral T and B cells from
patients with JSLE, but not from patients with JRA
and JDM.
Fas and Bcl-2 proteins play a signiﬁcant role in
lymphocyte proliferation, survival and apoptosis
(Kamradt and Mitchinson 2001). It is not clear
how apoptosis relates to the pathogenesis of
autoimmune diseases (Andrade et al. 2000).
However, there is a hypothesis that accelerated
apoptosis of circulating lymphocytes might lead to
the release of increased amounts of intact nuclear
antigens that can drive to an autoimmune response
and to combine with autoantibodies to form
immune complexes (Wyllie 1997; Andrade et al.
2000). Some studies have shown that lymphocytes
Table I. Percentage of lymphocytes positive stained for Fas—mean ^ SD.
Subjects N8 CD3 þ T cells CD4 þ T cells CD8 þ T cells CD19 þ B cells
JSLE 38 43.7 ^ 10.3 20.3 ^ 6.7 21.5 ^ 9.6 2.1 ^ 1.4
JRA 19 34.9 ^ 10.6* 18.2 ^ 3.9 17.3 ^ 9.7* 1.4 ^ 0.7*
JDM 10 24.9 ^ 13.4* 13.0 ^ 4.0* 12.7 ^ 13.5* 1.6 ^ 0.8
Healthy controls 25 31.2 ^ 9.1* 17.9 ^ 6.3 12.5 ^ 5.9* 1.2 ^ 0.5*
JSLE, juvenile systemic lupus erythematosus; JRA, juvenile rheumatoid arthritis; JDM, juvenile dermatomyositis; *p , 0.05 JSLE vs. healthy
controls, JRA or JDM; Kruskal–Wallis test.
Table II. MFI of Bcl-2 positive lymphocytes—mean ^ SD.
Subjects N8 CD3 þ T cells CD4 þ T cells CD8 þ T cells CD19 þ B cells
JSLE 38 28.8 ^ 8.4 28.6 ^ 8.2 29.4 ^ 9.3 25.5 ^ 9.6
JRA 19 24.4 ^ 4.4* 23.6 ^ 4.6* 23.9 ^ 5.7* 22.3 ^ 5.3
JDM 10 26.9 ^ 8.4 25.7 ^ 7.5 29.5 ^ 8.9 22.3 ^ 4.8
Healthy controls 25 26.0 ^ 7.2* 25.9 ^ 7.2* 25.5 ^ 6.7* 23.6 ^ 5.6
JSLE, juvenile systemic lupus erythematosus; JRA, juvenile rheumatoid arthritis; JDM, juvenile dermatomyositis; *p , 0.05 JSLE vs. healthy
controls, JRA or JDM; Kruskal–Wallis test.
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at signiﬁcant greater rates than lymphocytes from
healthy controls (Emlen et al. 1994; Chan et al.
1997; Smolewska et al. 2003).
Experimental studies revealed that MRL/Ipr mice
have a mutation of Fas gene that prevents expression
and cell death. These mice develop a lymphoproli-
ferative syndrome including features resembling
human lupus (Rieax-Laucat et al. 1995; Drappa et al.
1996). Transgenic mice overexpressing Bcl-2 protects
B cells against cell death and it promotes the
development of a lupus-like autoimmune syndrome
with nephritis and autoantibodies (Strasser et al.
1991; Rose et al. 1994). It is likely that abnormal
expression of Fas antigen can increase the exposure
of hidden antigens and abnormal expression of
Bcl-2 inhibits removal of auto-reactive cells, thus
leading to an autoimmune disease (Andrade et al.
2000). Although recent data suggest a relation
between increased Fas and Bcl-2 expression
and lupus pathogenesis, it is not know if these
abnormalities are primaryor due to chronic inﬂamma-
tion and whether they can occur in other autoimmune
diseases.
The present study demonstrated increased percen-
tages of Tand B lymphocytes positively stained for Fas
antigen from JSLE patients compared to healthy
controls, JRA and JDM patients. Increased expression
of Fas antigen on CD3 þ T lymphocytes was also
showed by Courtney et al. (1999). Unlike the present
results, Amasaki et al. (1995) observed increased
expression of Fas antigen on CD4 þ and CD8 þ
T cells from lupus patients compared to healthy
controls. Bijl et al. (2001) also showed a higher
expression of Fas protein on B lymphocytes from
patients with lupus. And Ohsako et al. (1994)
observed increased Fas expression on B cells from
lupus patients with active disease. Szodoray et al.
(2003) observed an underexpression of pro-apoptotic
proteins Fas and Bax on lymphocytes from patients
with rheumatoid arthritis. Sioud et al. (1998)
demonstrated increased expression of Fas protein on
synovial ﬂuid CD3 þ T cells from patients with
rheumatoid arthritis and JRA. On dermatomyositis
patients, Behrens et al. (1997) and Sugiura et al.
(1999) observed increased expression of Fas in muscle
ﬁbres and inﬂammatory cells. In addition, we
observed increased expression of Fas protein on
CD3 þ , on CD4 þ and on CD8 þ T cells from
patients with JRA compared to JDM patients. Fas
antigen is the main protein related to apoptosis
induction. Apoptosis might usually be induced in
activated lymphocytes, which would lead to a more
rapid turnover of these cells and a greater exposure of
autoantigens (Kamradt and Mitchinson 2001). This
study is also in accordance to the suggestion that
increased expression of Fas antigen and enhancement
of apoptotic material may be a hallmark of lupus and
probably not related to chronic inﬂammation (Ohsako
et al. 1994; Amasaki et al. 1995; Bijl et al. 2001).
Expression of apoptosis-inhibitory protein Bcl-2 on
freshly isolated lymphocytes has been a matter of
controversy. Some investigators have shown increased
Bcl-2 expression in T cells, but not on B cells while
others demonstrated unaltered Bcl-2 quantities in
unfractionated lymphocytes in adult patients with
lupus (Hockenbery et al. 1993; Aringer et al. 1994;
Mehrian et al. 1998; Falcini et al. 1999; Ivanovska
et al. 2004). The present study showed a signiﬁcantly
increased Bcl-2 expression on all T lymphocytes
subsets compared to healthy controls. These results
are similar to that observed by Aringer et al. (1994)
and Ohsako et al. (1994). Otherwise, Rose et al.
(1995) observed a similar expression of Bcl-2 protein
on lupus patients and healthy controls and Chan et al.
(1997) demonstrated decreased expression of Bcl-2
protein on lymphocytes from patients with lupus. On
juvenile-onset SLE patients Falcini et al. (1999) also
observed a higher expression of Bcl-2 protein on T
lymphocytes,but not on B cells. Szodorayet al. (2003)
observed increased expression of Bcl-2 protein on
lymphocytes from patients with rheumatoid arthritis,
possibly resulting in increased survival of auto-
reactive lymphocytes. Behrens et al. (1997) observed
increased expression of Bcl-2 in muscle ﬁbres and
inﬂammatory cells form patients with dermatomyosi-
tis. Indeed, this study supports a possible role of
increased expression of Bcl-2 on JSLE pathogenesis
considering that it may lead to longevity
and persistence of auto-reactive lymphocyte clones
(Hockenbery et al. 1993; Andrade et al. 2000;
Kamradt and Mitchinson 2001).
Interestingly, Fas and Bcl-2 expressions on Tand B
lymphocytes from JRA and JDM patients were
indistinguishable from their expression on lympho-
cytes from healthy controls, suggesting that the altered
Fas and Bcl-2 expression observed on lymphocytes
may be at least somewhat speciﬁc for JSLE. However,
whether the abnormalities of apoptosis observed
herein in JSLE patients could be considered a primary
pathogenic event or, alternatively, a secondary
epiphenomenon it remains to be elucidated. Compar-
ing our results to others studies, it can be suggest that
on JRA and JDM patients the expression of apoptotic
regulated proteins is important in determining local
inﬂammation such as chronic synovitis and muscle
lesion, but it is not a systemic alteration observed on
peripheral lymphocytes like on patients with JSLE
(Behrens et al. 1997; Sioud et al. 1998; Sugiura et al.
1999; Falcini et al. 2000).
In conclusion, the results presented herein showed
that a dysregulation of apoptosis occurs in JSLE
patients somewhat similarly to adult patients with
lupus, considering the increased expression of Fas
and Bcl-2 proteins on T and B lymphocytes. These
data also suggest that these alterations are somewhat
B. L. Liphaus et al. 286exclusive to JSLE patients and not only related to
chronic inﬂammation.
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